No Radioactive Roads Act of 2025
- Sponsor
- Rep. Frost, Maxwell [D-FL-10]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jul 22, 2025
Bottom line
This bill codifies and strengthens EPA's existing stance against the widespread use of phosphogypsum in applications like road construction by establishing strict risk assessment and public transparency requirements for any alternative uses.
What it actually does
This bill directs the Administrator of the Environmental Protection Agency (EPA) to revise existing regulations (40 CFR 61.206) within two years to establish strict requirements for approving any non-specified distribution or use of phosphogypsum. It mandates that approval requests include detailed risk assessments, exposure minimization plans, and comprehensive environmental monitoring programs. Crucially, it prohibits categorical approvals, requires case-by-case determinations, and sets a maximum individual lifetime cancer risk threshold of 9.1 in 100,000, while also requiring public disclosure of all approval requests and testing results.
Proponents argue
Proponents argue that the bill is essential for protecting public health and safety by preventing exposure to radioactive materials in phosphogypsum, especially for construction workers and nearby residents, and ensures environmental protection from leaching contaminants. They emphasize the cumulative nature of radiation exposure and the EPA's prior findings on cancer risks, asserting that the bill reinforces a necessary precautionary principle.
Opponents contend
Opponents might argue that the bill unnecessarily restricts the beneficial reuse of a waste product, potentially increasing disposal costs for the phosphate industry and limiting innovative solutions for material management. They might contend that current EPA regulations are sufficient or that specific, controlled uses could be safely managed without such stringent, codified requirements.
The bill is short and clearly written, allowing for a quick and comprehensive understanding of its provisions.
Section 1
Short Title: "No Radioactive Roads Act of 2025"
This section establishes the official short title of the Act as the "No Radioactive Roads Act of 2025." This title clearly communicates the bill's primary purpose and public health focus regarding the use of phosphogypsum, particularly in preventing its application in road construction and other potentially hazardous scenarios. It serves as a concise identifier for the legislation.
Supporters argue
Supporters argue that a clear and descriptive short title helps communicate the bill's intent to the public and stakeholders, emphasizing its focus on preventing radioactive materials in infrastructure and protecting public health.
Critics contend
No specific opposition is typically raised against the short title of a bill, as it is primarily for identification and public communication.
Tradeoffs
None apparent for the short title itself.
Section 2
Congressional Findings on Risks of Phosphogypsum Use
This section outlines Congress's findings regarding the dangers of phosphogypsum. It highlights the EPA's 1992 prohibition of its use in road construction due to cancer risks from uranium and radium, potential contamination of surface and groundwater through leaching, and air contamination from resuspended radioactive material. The findings also cite the EPA's established lifetime cancer risk threshold of 9.1 in 100,000 for phosphogypsum stacking and acknowledge the EPA's stance against categorical approvals for other uses.
Section 3(a)
Mandate for EPA Regulatory Revision
This provision directs the EPA Administrator to revise section 61.206 of title 40, Code of Federal Regulations, within two years of the Act's enactment. The revision must ensure that any request for approval to distribute or use phosphogypsum for purposes not already specified (i.e., not road construction or agricultural use) includes a maximum individual risk assessment, detailed measures to minimize exposure for various individuals (construction workers, utility workers, product users, nearby residents), and a comprehensive monitoring program for surface and groundwater contamination, including leachate and ecotoxicity estimates.
Section 3(a)(2)
Case-by-Case Approval and Maximum Risk Limit
This section mandates that any EPA approval for non-specified uses of phosphogypsum must be determined on a case-by-case basis, explicitly prohibiting categorical approvals. Furthermore, it establishes a strict maximum individual lifetime cancer risk threshold of 9.1 in 100,000 that no approved use may exceed. This threshold is directly linked to the risk level associated with the regulated stacking of phosphogypsum, ensuring consistency in risk management.
Section 3(a)(3)
Public Disclosure of Approval Requests and Testing Results
This provision requires that any request submitted to the Administrator for approval to distribute or use phosphogypsum for non-specified purposes, including all results from the required environmental testing (such as leachate and ecotoxicity monitoring), must be made publicly available on the official website of the Environmental Protection Agency. This ensures transparency in the regulatory process.
Section 3(b)
Definition of "Maximum Individual Risk"
This section provides a precise definition for the term "maximum individual risk" as it is used within the Act. It clarifies that this term refers to the highest increase in lifetime cancer risk an individual faces within a population that is exposed to the highest concentration of phosphogypsum over a 70-year period. This standardized definition ensures consistent application of the risk threshold established in the bill.
Requires any request for phosphogypsum use approval to include a detailed monitoring program for surface and groundwater, encompassing estimates of leachate amount and composition, ecotoxicity impacts, and a written plan for quarterly leachate and ecotoxicity monitoring of nearby and downstream environments (soil, vegetation, waterways, aquatic life).
Section 3(a)(1)(C)
Why it matters:This is standard legislative practice for specifying operational details within a broader regulatory mandate, ensuring that the implementing agency has clear instructions on the scope of required information.
Case for: Supporters argue that these specific and frequent monitoring requirements are essential to ensure comprehensive environmental protection, providing early detection of contamination and holding applicants accountable for potential impacts on ecosystems and water sources.
Case against: Industry groups might argue that such detailed and frequent monitoring requirements are overly prescriptive and costly, potentially creating unnecessary burdens for projects with low actual risk and increasing the overall expense of managing phosphogypsum.
Estimated impact: Significantly increases the data collection and reporting burden for any entity seeking to use phosphogypsum for non-specified purposes, leading to higher compliance costs and requiring specialized environmental assessments.